This brand name is authorized in Finland.
The drug DEPO-MEDROL CUM LIDOCAIN contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
43502P7F0P - METHYLPREDNISOLONE ACETATE
|
|
Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system. |
|
2
|
UNII
V13007Z41A - LIDOCAINE HYDROCHLORIDE
|
|
Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| H02BX01 | Methylprednisolone, combinations | H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS → H02BX Corticosteroids for systemic use, combinations |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 134643, 136085 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.